%0 Journal Article
%A Besse, Benjamin
%A Lin, Jessica J
%A Bazhenova, Lyudmila
%A Goto, Koichi
%A de Langen, Adrianus Johannes
%A Kim, Dong-Wan
%A Wolf, Jürgen
%A Springfeld, Christoph
%A Popat, Sanjay
%A Lim, Darren W T
%A Nagasaka, Misako
%A Hong, Jung Yong
%A Baik, Christina S
%A Hervieu, Alice
%A Moreno, Victor
%A Yang, Nong
%A Kollengode, Kanthi
%A Yang, Haisu
%A Xu, Yuanfang
%A Calvet, Christophe Y
%A Yuan, Yong
%A Hammell, Amy B
%A Drilon, Alexander
%A Solomon, Benjamin J
%T Repotrectinib in NTRK fusion-positive advanced solid tumors: a phase 1/2 trial.
%J Nature medicine
%V nn
%@ 1078-8956
%C [New York, NY]
%I Springer Nature
%M DKFZ-2026-00289
%P nn
%D 2026
%Z #NCTZFB9# / epub
%X Early-generation TRK tyrosine kinase inhibitors (TKIs) approved for treating NTRK fusion-positive (NTRK+) solid tumors provide clinical benefit; however, resistance emerges. Repotrectinib is a next-generation ROS1/TRK TKI with a compact macrocyclic structure designed to improve durability of response. TRIDENT-1 is a registrational phase 1/2 trial assessing repotrectinib, a next-generation ROS1/TRK TKI, in adults with advanced solid tumors, including NTRK+ disease. The primary endpoint was confirmed objective response; secondary endpoints included duration of response (DOR), progression-free survival (PFS), overall survival and safety. Median follow-up ranged between 21.3 months and 25.7 months. In the TKI-naive cohort (n = 51; 95
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:41639379
%R 10.1038/s41591-025-04079-7
%U https://inrepo02.dkfz.de/record/309657